326 related articles for article (PubMed ID: 30627896)
21. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
Wei QY; Wu YQ; Fan SQ
Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
[TBL] [Abstract][Full Text] [Related]
22. Matrix metalloproteinase 2 (MMP-2) and their tissue inhibitor 2 (TIMP-2) in gastric cancer patients.
Łukaszewicz-Zając M; Mroczko B; Guzińska-Ustymowicz K; Pryczynicz A; Gryko M; Kemona A; Kędra B; Szmitkowski M
Adv Med Sci; 2013; 58(2):235-43. PubMed ID: 24384769
[TBL] [Abstract][Full Text] [Related]
23. MMP-2 and MMP-9 as prognostic markers for the early detection of urinary bladder cancer.
Fouad H; Salem H; Ellakwa DE; Abdel-Hamid M
J Biochem Mol Toxicol; 2019 Apr; 33(4):e22275. PubMed ID: 30548095
[TBL] [Abstract][Full Text] [Related]
24. Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples.
Pesta M; Holubec L; Topolcan O; Cerna M; Rupert K; Holubec LS; Treska V; Kormunda S; Elgrova L; Finek J; Cerny R
Anticancer Res; 2005; 25(5):3387-91. PubMed ID: 16101153
[TBL] [Abstract][Full Text] [Related]
25. MMP, VEGF and TIMP as prognostic factors in recurring bladder cancer.
Wieczorek E; Jablonowski Z; Tomasik B; Konecki T; Jablonska E; Gromadzinska J; Fendler W; Sosnowski M; Wasowicz W; Reszka E
Clin Biochem; 2015 Dec; 48(18):1235-40. PubMed ID: 26197083
[TBL] [Abstract][Full Text] [Related]
26. Comparative Role of Matrixins in Diagnostics of Parotid Gland Tumors.
Kochurova EV
Bull Exp Biol Med; 2019 Jan; 166(3):383-385. PubMed ID: 30617705
[TBL] [Abstract][Full Text] [Related]
27. Prognostic role of tumor-associated proteases in colorectal cancer.
Kushlinskii NE; Gershtein ES; Korotkova EA; Prorokov VV
Bull Exp Biol Med; 2013 Jan; 154(3):365-9. PubMed ID: 23484202
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological significance of MMP-2 and TIMP-2 genotypes in gastric cancer.
Wu CY; Wu MS; Chen YJ; Chen CJ; Chen HP; Shun CT; Chen GH; Huang SP; Lin JT
Eur J Cancer; 2007 Mar; 43(4):799-808. PubMed ID: 17236757
[TBL] [Abstract][Full Text] [Related]
29. [Expression and clinical significance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma].
Fan SQ; Wei QY; Li MR; Zhang LQ; Liang QC
Ai Zheng; 2003 Sep; 22(9):968-73. PubMed ID: 12969531
[TBL] [Abstract][Full Text] [Related]
30. Significance of circulating matrix metalloproteinase-9 to tissue inhibitor of metalloproteinases-2 ratio as a predictor of disease progression in patients with metastatic renal cell carcinoma receiving sunitinib.
Miyake H; Nishikawa M; Tei H; Furukawa J; Harada K; Fujisawa M
Urol Oncol; 2014 Jul; 32(5):584-8. PubMed ID: 24680659
[TBL] [Abstract][Full Text] [Related]
31. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
[TBL] [Abstract][Full Text] [Related]
32. Plasma level of tissue inhibitor of matrix metalloproteinase-1 but not that of matrix metalloproteinase-8 predicts survival in head and neck squamous cell cancer.
Pradhan-Palikhe P; Vesterinen T; Tarkkanen J; Leivo I; Sorsa T; Salo T; Mattila PS
Oral Oncol; 2010 Jul; 46(7):514-8. PubMed ID: 20371206
[TBL] [Abstract][Full Text] [Related]
33. Matrix metalloproteinases 2, 7, 9 and tissue inhibitor of matrix metalloproteinase-1 in the sera of patients with bone tumors.
Kushlinsky NE; Solovyov YN; Babkina IV; Gershtein ES; Bulicheva IV
Bull Exp Biol Med; 2010 Aug; 149(2):233-5. PubMed ID: 21113498
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with gastric cancer.
Yoshikawa T; Tsuburaya A; Kobayashi O; Sairenji M; Motohashi H; Yanoma S; Noguchi Y
Cancer Lett; 2000 Apr; 151(1):81-6. PubMed ID: 10766426
[TBL] [Abstract][Full Text] [Related]
35. Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker.
Wang CS; Wu TL; Tsao KC; Sun CF
Ann Clin Lab Sci; 2006; 36(1):23-30. PubMed ID: 16501233
[TBL] [Abstract][Full Text] [Related]
36. Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma.
Zhang S; Li L; Lin JY; Lin H
World J Gastroenterol; 2003 May; 9(5):899-904. PubMed ID: 12717827
[TBL] [Abstract][Full Text] [Related]
37. [How to predict the relapse after surgery or radiofrequency of liver metastases of colorectal cancer? Interest of the serum kinetic variation of a matrix metalloproteinase cluster].
Frenoux C; Rebischung C; Quesada JL; Mendosa C; Letoublon C; Trocmé C
Bull Cancer; 2018 Oct; 105(10):884-895. PubMed ID: 30243479
[TBL] [Abstract][Full Text] [Related]
38. [Relationship of expression unbalance of matrix metalloproteinase and tissue inhibitor of metalloproteinase to invasiveness and metastasis in gastric carcinomas].
Li L; Zhang S; Lin H; Lin JY
Ai Zheng; 2002 Mar; 21(3):305-10. PubMed ID: 12452001
[TBL] [Abstract][Full Text] [Related]
39. Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer.
Endo K; Maehara Y; Baba H; Yamamoto M; Tomisaki S; Watanabe A; Kakeji Y; Sugimachi K
Anticancer Res; 1997; 17(3C):2253-8. PubMed ID: 9216697
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer.
Wu ZS; Wu Q; Yang JH; Wang HQ; Ding XD; Yang F; Xu XC
Int J Cancer; 2008 May; 122(9):2050-6. PubMed ID: 18172859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
